D. Boral Capital Reaffirms “Buy” Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research report issued on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright initiated coverage on shares of Humacyte in a research report on Wednesday, May 14th. They issued a “buy” rating and a $4.00 target price for the company. Benchmark decreased their target price on Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Finally, Wall Street Zen raised Humacyte from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Humacyte has an average rating of “Moderate Buy” and a consensus price target of $11.71.

Humacyte Stock Up 4.3%

Shares of HUMA stock opened at $2.67 on Monday. Humacyte has a 52-week low of $1.15 and a 52-week high of $9.79. The business has a 50-day simple moving average of $1.84 and a 200-day simple moving average of $3.19. The stock has a market cap of $414.17 million, a PE ratio of -1.99 and a beta of 2.00.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.46 million. Sell-side analysts anticipate that Humacyte will post -1.27 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Dale A. Sander purchased 20,000 shares of the stock in a transaction that occurred on Thursday, April 10th. The shares were purchased at an average price of $1.53 per share, with a total value of $30,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 40,600 shares in the company, valued at $62,118. This represents a 97.09% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kathleen Sebelius acquired 50,000 shares of the stock in a transaction that occurred on Tuesday, April 8th. The stock was acquired at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the purchase, the director now owns 91,207 shares in the company, valued at $120,393.24. The trade was a 121.34% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 83,993 shares of company stock valued at $118,224 over the last quarter. Company insiders own 5.10% of the company’s stock.

Institutional Trading of Humacyte

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Columbia Advisory Partners LLC acquired a new stake in Humacyte during the first quarter worth approximately $27,000. Hamilton Lane Advisors LLC purchased a new position in Humacyte during the first quarter worth about $37,000. Letko Brosseau & Associates Inc. acquired a new stake in Humacyte in the 1st quarter worth about $42,000. Vontobel Holding Ltd. purchased a new stake in Humacyte in the 4th quarter valued at about $50,000. Finally, Petros Family Wealth LLC acquired a new stake in shares of Humacyte in the fourth quarter worth approximately $50,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.